Ribavirin treatment
in M4/M5 acute myeloid leukemia patients
Thanks to the support of The Leukemia and Lymphoma Society
(USA), a Canada-wide Phase I/II clinical trial will be carried
out to monitor the use of Ribavirin as a novel therapy in the
treatment of M4/M5 acute myeloid leukemia patients. This trial
stems from pre-clinical studies indicating that Ribavirin suppresses
the activities of a cellular factor, eIF4E, which is involved
in making cells cancerous.
The study team is led by Dr Katherine
Borden at the Institute for Research in Immunology and Cancer
(IRIC) at the Université de
Montréal and involves several sites throughout Canada.
The clinical trial will be managed from the Clinical Research
Unit at the Jewish General Hospital, a McGill University affiliated
Hospital. For more information about the trial please
contact Dr Effie Cocolakis, the study coordinator (ecocolakis@jgh.mcgill.ca)
|